Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism.
We report the vascular surgical strategies and results in 13 patients with heparin-associated thrombocytopenia and describe useful in vitro techniques for the evaluation of anticoagulant therapy. Thirteen of 40 patients with heparin-associated thrombocytopenia had 18 cardiovascular procedures done to save life or limb. Greenfield filters were placed in eight patients to prevent pulmonary embolism. Eight patients had 10 arterial procedures, with alternative anticoagulation that used dextran or warfarin in five cases. In three cases iloprost, a derivative of prostacyclin and a potent platelet inhibitor, was infused intraoperatively and heparin was given. Both the use of alternative anticoagulants and platelet suppression by iloprost were clinically effective strategies. The concurrent measurement of plasma levels of beta-thromboglobulin and fibrinopeptide A in two patients confirmed that both approaches can successfully prevent activation of platelets and plasma coagulation during arterial surgery. One operative death occurred; all vascular reconstructions remained patent at 3 to 6 months. In two patients who received heparin alone for arterial surgery, both procedures resulted in thrombosis and limb loss. When major venous thromboembolism is complicated by heparin-associated thrombocytopenia, insertion of a Greenfield vena cava filter should be considered if there is significant risk of pulmonary embolism. When necessary, arterial surgery is feasible in patients with heparin-associated thrombocytopenia if alternative anticoagulation or adequate suppression of platelet reactivity can be achieved.
Sobel
M
M
Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Adelman
B
B
Szentpetery
S
S
Hoffman
M
M
Posner
M P
MP
Jenvey
W
W
D003911:Dextrans / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D005374:Filtration / Q000295:instrumentation*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D016285:Iloprost; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000517:prevention & control*; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced*; D013923:Thromboembolism / Q000601:surgery*; D014682:Vena Cava, Inferior; D014859:Warfarin / Q000627:therapeutic use
D003911:Dextrans; D014859:Warfarin; D006493:Heparin; D011464:Epoprostenol; D016285:Iloprost